Clinical Trials Logo

Hyperbilirubinemia clinical trials

View clinical trials related to Hyperbilirubinemia.

Filter by:

NCT ID: NCT03675425 Active, not recruiting - Clinical trials for Patent Ductus Arteriosus After Premature Birth

The Effects of Phototherapy in Preterm Infants Pda

Start date: July 8, 2018
Phase: N/A
Study type: Interventional

The study was designed to assess whether chest shielding during phototherapy reduces the incidence of PDA, as assessed by serial echocardiographic examinations, in a population of extremely preterm infants born at lower 30 week gestation.

NCT ID: NCT03624335 Completed - Clinical trials for Hyperbilirubinemia, Neonatal

Influence of Umbilical Cord Clamping Time in the Newborn

Start date: March 23, 2015
Phase: N/A
Study type: Interventional

This study compares two umbilical cord clamping times; the early one, up to a minute (ECC) and the late or delayed one, when the cord stop beating (DCC). The additional blood volume delivered to the newborn from the placenta - placental transference - by delaying umbilical cord ligation, increases the contribution of neonatal iron with increased iron stores in the infant, without increasing neonatal morbidity.

NCT ID: NCT03599258 Completed - Jaundice, Neonatal Clinical Trials

Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns

Start date: April 15, 2018
Phase: N/A
Study type: Interventional

Phototherapy has served as a primary treatment for hyperbilirubinemia in newborn populations. The light emitted through phototherapy interacts with bilirubin at the skin level to transform it into water-soluble products eliminated in urine and stool. Efficacy of phototherapy relies on the irradiance dispensed at the skin level by the treatment and on the surface area of skin exposed. The purpose of this Investigator-initiated, prospective, two-arm, randomized control investigation is to compare the effect of a novel, newly available, FDA cleared, phototherapy device (Neolight Skylife) with the standard phototherapy treatments used in HonorHealth newborn nurseries (Natus-Neo Blue Blanket and GE Bili Soft Blanket) on healthy, newborns ≥ 35 weeks + 0 days Gestational Age (GA) at the time of birth in the treatment of hyperbilirubinemia. We hypothesize that the unconjugated bilirubin level will be comparably reduced across each treatment arm from baseline to 12 and 24 hour intervals.

NCT ID: NCT03564678 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

Start date: May 17, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well levocarnitine and vitamin B complex works in treating abnormal high liver enzyme levels (hyperbilirubinemia) caused by treatment with PEG-asparaginase or inotuzumab ozogamicin in patients with acute lymphoblastic leukemia. Amino acids, such as levocarnitine, may work in normalizing liver enzyme levels due to treatment. Vitamin B complex is a dietary supplement that may be used for patients with nutritional deficiencies. Giving levocarnitine and vitamin B complex may work better in treating hyperbilirubinemia in patients with acute lymphoblastic leukemia.

NCT ID: NCT03536078 Completed - Clinical trials for Neonatal Hyperbilirubinemia

Home Phototherapy for Term Newborns With Icterus

Start date: June 30, 2016
Phase: N/A
Study type: Interventional

The study is designed as a randomised controlled multicenter study.The primary aim is to investigate if home phototherapy improves parent-child bonding compared to if treatment is performed at the hospital. The investigators will also istudy how home phototherapy is perceived by the parents, impact on breastfeeding and parents stress levels, if the method can be implemented etc. Patients are included at 5 hospitals in Sweden. The plan is to include 250 term newborns with neonatal icterus at a level that needs phototherapy treatment.

NCT ID: NCT03329040 Completed - Clinical trials for Hyperbilirubinemia, Neonatal

Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia?

Start date: January 1, 2018
Phase:
Study type: Observational

Neonatal hyperbilirubinemia elongates hospital stay and may require treatment. The investigators noticed that bilirubin levels were higher among infants of primipara mothers than among multipara mothers. As this data is dichotomic and easy to produce, and may influence the maintenance, the investigators decided to find out if primiparity is a risk factor for neonatal hyperbilirubinemia. The investigators intend to collect data from patient files during one year, and compare the bilirubin levels and length of stay between newborns to primipara mothers and multipara mothers.

NCT ID: NCT03266913 Recruiting - Clinical trials for Hyperbilirubinemia, Neonatal

Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia

Start date: August 1, 2017
Phase: Phase 3
Study type: Interventional

Neonatal Jaundice occurs in 60% of term infants and 80% of premature infants. Although it is transient, it is associated with high rate of readmission of patients in the first week of infancy. Neonatal jaundice can cause neurological complications and kernicterus. Considering the fact that there have been a lot of studies on probiotic role in management of necrotizing enterocolitis (NEC) and few studies on their role in neonatal jaundice, we carried out this study to determine the efficacy and safety of probiotics in neonatal hyperbilirubinemia in infants hospitalized in children hospital in Bandar Abbas.

NCT ID: NCT03259581 Completed - Clinical trials for Hepatocellular Carcinoma

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

Start date: January 2, 2018
Phase: Phase 1
Study type: Interventional

The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.

NCT ID: NCT03195998 Completed - Hyperbilirubinemia Clinical Trials

Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants

TcB
Start date: June 30, 2017
Phase:
Study type: Observational

The most common and widely accepted method of monitoring bilirubin levels in neonates is the use of the laboratory analyzation of serum blood levels. Unfortunately this method is invasive, painful, and can progressively lead to increased blood loss in the neonate. It also requires the use of additional time and resources to coordinate sending the sample to the laboratory and processing the specimen in the lab. There exists a different option for obtaining bilirubin levels in neonates which is the transcutaneous bilirubinometer. This device detects bilirubin levels at the bedside and has been validated for use in infants born at > 35 weeks gestation. There are a limited number of studies evaluating its use in premature infants. Our aim is to assess the diagnostic accuracy and efficacy of transcutaneous bilirubinometry (TcB) of the Dräger JM-103 by comparing (TcB) readings to total serum bilirubin (TSB) results in neonates born at 23 0/7-34 6/7 weeks gestation.

NCT ID: NCT03074292 Active, not recruiting - Oxidative Stress Clinical Trials

Comparison Between Effect of Conventional, Intensive and Light Emitting Diodes (LED) Phototherapy on Oxidative Stress Among Neonates With Unconjugated Hyperbilirubinemia

Start date: December 2013
Phase: N/A
Study type: Interventional

The aim of the present study is to test a hypothesis assuming that phototherapy might have an effect on oxidant/antioxidant status in term and late-preterm neonates with unconjugated hyperbilirubinemia.